Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbetocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR known ✓ | P30559 | 15/20 | 0.97 |
| ▸ | AVPR1A | P37288 | 11/20 | 0.97 |
| ▸ | AVPR2 | P30518 | 10/20 | 0.97 |
| ▸ | AVPR1B | P47901 | 6/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbetocin SCHEMBL3128368 | 0.99 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL19712191 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL28528620 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118157 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL39224 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118135 | 0.96 | OXTR (0.94) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118146 | 0.96 | OXTR (0.94) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118116 | 0.96 | OXTR (0.94) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118144 | 0.95 | OXTR (0.93) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL21807451 | 0.95 | OXTR (0.91) | OXTRAVPR1AAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106538-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-15 | — | — | US | claimed |
| EP-3471778-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | claimed |
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | claimed |
| WO-2017223085-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-28 | — | — | WO | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250375388-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | UNIV MICHIGAN REGENTS (US) | 2025-12-11 | — | — | US | disclosed |
| US-12403177-B2 | Silk-based product formulations and methods of use | COCOON BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-07-03 | — | — | US | disclosed |
| US-12257352-B2 | Compositions and methods for delivery of biomacromolecule agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250060360-A1 | MACRO TISSUE EXPLANT, METHODS AND USES THEREFOR | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-02-20 | — | — | US | disclosed |
| US-20240352079-A1 | Silk-Based Products, Formulations, and Methods of Use | COCOON BIOTECH INC. | 2024-10-24 | — | — | US | disclosed |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | disclosed |
| WO-2020247594-A1 | SILK-BASED PRODUCTS, FORMULATIONS, AND METHODS OF USE | COCOON BIOTECH INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| CN-111548391-A | Drying and filtering system for carbetocin | 山东辰龙药业有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-111060635-A | Analysis and detection method of carbetocin | 吉尔生化（上海）有限公司 | 2020-04-24 | — | — | CN | disclosed |
| EP-3601527-A1 | MACRO TISSUE EXPLANT, METHODS AND USES THEREFOR | Massachusetts Institute of Technology (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3471778-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2018175861-A1 | MACRO TISSUE EXPLANT, METHODS AND USES THEREFOR | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | disclosed |
| WO-2017223085-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | OXTR 4849/4885AVPR1A 4759/4885AVPR2 4856/4885 |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | STING1, CGAS, IRF3 | OXTR 4270/4885AVPR1A 3107/4885AVPR2 4305/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | OXTR 4733/4885AVPR1A 4440/4885AVPR2 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.